ArticleJournal of substance abuse treatment2017
Long-term retention in Office Based Opioid Treatment with buprenorphine.
Article in Journal of substance abuse treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05299515 (Peer-Delivered Behavioral Activation Intervention to Improve Adherence to MT Among Low-Income, Minority Individuals With OUD), which is not on this map. Cited by 134 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Peer-Delivered Behavioral Activation Intervention to Improve Adherence to MT Among Low-Income, Minority Individuals With OUD
Who cites it
134 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Diversity inclusion in United States opioid pharmacological treatment trials: A systematic review.Experimental and clinical psychopharmacology · 2021Pooled it
- Adherence to and Retention in Medications for Opioid Use Disorder Among Adolescents and Young Adults.Epidemiologic reviews · 2020Pooled it
- Pooled it
- Effectiveness of medication assisted treatment for opioid use in prison and jail settings: A meta-analysis and systematic review.Journal of substance abuse treatment · 2019Pooled it
- Differences in benefits of office based opioid treatment: Secondary analyses across sub-groups in the PROUD randomized controlled implementation trial.Addiction (Abingdon, England) · 2026Trial
- Effects of the Communities That HEAL intervention on initiation, retention, and linkage to medications for opioid use disorder (MOUD): A cluster randomized wait-list controlled trial.Drug and alcohol dependence · 2025Trial
- A randomized pilot trial of two forms of behavioral economics intervention to improve engagement in buprenorphine-naloxone treatment among patients with opioid use disorder.Drug and alcohol dependence · 2025Trial
- Does implementation of office based addiction treatment by a nurse care manager increase the duration of OUD treatment in primary care? A secondary analysis of the PROUD randomized control trial.Drug and alcohol dependence · 2024Trial
- Gender differences in outcomes of early intervention services for first episode psychosis.Early intervention in psychiatry · 2023Trial
- Video directly observed therapy for patients receiving office-based buprenorphine - A pilot randomized controlled trial.Drug and alcohol dependence · 2021Trial
- A pilot study of mindful body awareness training as an adjunct to office-based medication treatment of opioid use disorder.Journal of substance abuse treatment · 2020Trial
- Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder.Journal of substance abuse treatment · 2019Trial
- Understanding site variability in a multisite clinical trial of a technology-delivered psychosocial intervention for substance use disorders.Journal of substance abuse treatment · 2019Trial
- Continuity of Medications for Opioid Use Disorder in States With and Without Medicaid Prescription Cap Policies.Medical care · 2026Article
- Tailoring of a chronic pain self-management intervention for individuals with opioid use disorder in office-based addiction treatment.Journal of substance use and addiction treatment · 2026Article
- Differences in buprenorphine initiation and retention for opioid use disorder between primary care and substance use disorder specialty care settings.Journal of substance use and addiction treatment · 2026Article
- Retention among Medicaid beneficiaries in opioid treatment programs in California.Journal of substance use and addiction treatment · 2026Article
- Navigating opioid use disorder treatment for pregnant and parenting people: composite narratives for policy action.Substance abuse treatment, prevention, and policy · 2026Article
- Opioid overdose and cardiovascular disease-related mortality: a retrospective analysis using real-world data from the USA, 1999-2023.Frontiers in cardiovascular medicine · 2026Article
- Article
74 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundGuidelines recommend long-term treatment for opioid use disorder with buprenorphine; however, little is known about patients in long-term treatment. The aim of this study is to examine the prevalence and patient characteristics of long-term treatment retention (≥1year) in an Office Based Opioid Treatment (OBOT) program with buprenorphine.
methodsThis is a retrospective cohort study of adults on buprenorphine from January 2002 to February 2014 in a large urban safety-net primary care OBOT program. The primary outcome was retention in OBOT for at least one continuous year. Potential predictors included age, race, psychiatric diagnoses, hepatitis C, employment, prior buprenorphine, ever heroin use, current cocaine, benzodiazepine and alcohol use on enrollment. Factors associated with ≥1year OBOT retention were identified using generalized estimating equation logistic regression models. Patients who re-enrolled in the program contributed repeated observations.
resultsThere were 1605 OBOT treatment periods among 1237 patients in this study. Almost half, 45% (717/1605), of all treatment periods were ≥1year and a majority, 53.7% (664/1237), of patients had at least one ≥1year period. In adjusted analyses, female gender (Adjusted Odds Ratio [AOR] 1.55, 95% CI [1.20, 2.00]) psychiatric diagnosis (AOR 1.75 [1.35, 2.27]) and age (AOR 1.19 per 10year increase [1.05, 1.34]) were associated with greater odds of ≥1year retention. Unemployment (AOR 0.72 [0.56, 0.92]), Hepatitis C (AOR 0.59 [0.45, 0.76]), black race/ethnicity (AOR 0.53 [0.36, 0.78]) and Hispanic race/ethnicity (AOR 0.66 [0.48, 0.92]) were associated with lower odds of ≥1year retention.
conclusionsOver half of patients who presented to Office Based Opioid Treatment with buprenorphine were ultimately successfully retained for ≥1year. However, significant disparities in one-year treatment retention were observed, including poorer retention for patients who were younger, black, Hispanic, unemployed, or with hepatitis C.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.